Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The effects of different i.v. doses of glucagon-like peptide 1 (GLP-1) on glucose homeostasis and gastric emptying were compared in patients with type 2 diabetes. Twelve patients with type 2 diabetes received three different infusion rates of GLP-1 (0.4, 0.8, and 1.2 pmol/kg x min) or placebo in the fasting state and after a solid test meal (containing [(13)C]octanoic acid). Blood was drawn for glucose, insulin, C-peptide, glucagon, and GLP-1 determinations. The gastric emptying rate was calculated from the (13)CO(2) excretion rates in breath samples. Statistics were determined using repeated measures ANOVA and Duncan's post hoc test. Plasma glucose concentrations were equally normalized with all GLP-1 doses (P < 0.001). Insulin and C-peptide concentrations dose-dependently rose during GLP-1 infusion in the fasting state (P < 0.05), but were dose-dependently reduced by GLP-1 after meal ingestion (P = 0.0031 and 0.0074, respectively). Glucagon secretion was suppressed with GLP-1. Gastric emptying was decelerated by GLP-1 in a dose-dependent fashion (P < 0.001). Despite a dose-dependent stimulation of insulin secretion, glucose normalization can be achieved even with 0.4 pmol GLP-1/kg x min. Due to the dose-dependent inhibition of gastric emptying, lower GLP-1 doses than previously used may be as suitable for glucose control in patients with type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This dosing regimen produced supraphysiological plasma levels and normalized blood glucose concentrations in type II DM (23).”
From Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans (2008) · cites this paper as [23]
In the citing paper
“The inhibitory effect of GLP-1 on gastric emptying is dose-dependent, and the use of lower doses of GLP-1 in patients with T2DM may also be suitable for blood glucose control (141).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [141]
In the citing paper
“The inhibitory effect of GLP-1 on gastric emptying is dose-dependent, and the use of lower doses of GLP-1 in patients with T2DM may also be suitable for blood glucose control (141).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [141]
In the citing paper
“Furthermore, the action of GLP-1 and GLP-1 RAs (especially short acting) on gastric and intestinal cells causes, respectively, the deceleration of gastric emptying [31] and the reduction in intestine motility [32], which both impact the absorption of nutrients.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [31]
Citations
Cites
Intensive insulin therapy in critically ill patients.
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., & Bouillon, R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011300 · Cited by 9,977
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Self-citationZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“Nausea and vomiting have previously been reported after the administration of high GLP-1 doses in some (15, 18), but not all, studies (8, 21, 22).”
ResultSelf-citationMalmberg, K. (1997) · BMJ · doi:10.1136/bmj.314.7093.1512 · Cited by 1,286
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 3×
“However, in most previous studies comparably high doses of GLP-1 have been chosen for infusion (1, 9, 14).”
BackgroundResultSelf-citationGhoos, Y. F., Maes, B. D., Geypens, B. J., Mys, G., Hiele, M. I., Rutgeerts, P. J., & Vantrappen, G. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90640-x · Cited by 946
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationDeacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Self-citationStudies of pancreatic alpha cell function in normal and diabetic subjects
Unger, R. H., Aguilar-Parada, E., Müller, W. A., & Eisentraut, A. M. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106297 · Cited by 837
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Self-citation
Cited by
Items 101–119 of 119
Punjabi, M., Arnold, M., Rüttimann, E., Graber, M., Geary, N., Pacheco-López, G., & Langhans, W. (2014) · Endocrinology · doi:10.1210/en.2013-1447 · Cited by 59
Eleftheriadou, I., Grigoropoulou, P., Katsilambros, N., & Tentolouris, N. (2008) · Current Diabetes Reviews · doi:10.2174/157339908786241133 · Cited by 55
“Furthermore, GLP-1 inhibits gastric acid secretion and gastric emptying and thereby diminishes mealinduced glucose excursions, delays absorption of dietary triglycerides and it is likely to ameliorate postprandial lipemia [99, 100].”
BackgroundTesauro, M., Schinzari, F., Adamo, A., Rovella, V., Martini, F., Mores, N., Barini, A., Pitocco, D., Ghirlanda, G., Lauro, D., et al. (2013) · Diabetes Care · doi:10.2337/dc12-0763 · Cited by 54
“was assessed by infusing its metabolite GLP-1(9-36) (n = 5).”
BackgroundMethodInfluentialBray, G. M. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050459 · Cited by 52
Laparoscopic Sleeve Gastrectomy Resolves NAFLD: Another Formal Indication for Bariatric Surgery?
Esquivel, C. M., Garcia, M., Armando, L., Ortiz, G., Lascano, F. M., & Foscarini, J. M. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3466-7 · Cited by 51
Rhee, N. A., Vilsbøll, T., & Knop, F. K. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01505.x · Cited by 47
“GLP-1 is known to stimulate insulin secretion from pancreatic β cells [11,13]; inhibit glucagon secretion from pancreatic α cells [14] and decrease gastrointestinal motility [15], appetite [16], food intake [17] and body weight [18].”
BackgroundIntra-islet glucagon-like peptide 1
Fava, G. E., Dong, E. W., & Wu, H. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.016 · Cited by 45
Nauck, M. A., Kahle, M., Baranov, O., Deacon, C. F., & Holst, J. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12802 · Cited by 44
“quential improvements in glucose control can only partially be inhibited by the GLP-1 receptor agonist exendin [9-39].”
BackgroundMethodInfluentialSelf-citationChang, M. G., Ripoll, J. G., Lopez, E., Krishnan, K., & Bittner, E. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216336 · Cited by 43
“…doses of medications may result in a significant slowing of gastric emptying compared to lower dosing of medications using indirect measurements of gastric emptying, and that the duration of GLP-1 RA use may play a role given studies suggesting tachyphylaxis after prolonged GLP-1 RA use [63–66].”
BackgroundClinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist
Young, M. A., Wald, J. A., Matthews, J. E., Scott, R., Hodge, R. J., Zhi, H., & Reinhardt, R. R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2836 · Cited by 41
Kapitza, C., Zdravkovic, M., Hindsberger, C., & Flint, A. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0044-y · Cited by 36
Guo, H., Yang, J., Huang, J., Xu, L., Lv, Y., Wang, Y., Ren, J., Feng, Y., Zheng, Q., & Li, L. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100162 · Cited by 32
Effect of Afrezza on Glucose Dynamics During HCL Treatment
Galderisi, A., Cohen, N., Calhoun, P., Kraemer, K., Breton, M., Weinzimer, S., & Cengiz, E. (2020) · Diabetes Care · doi:10.2337/dc20-0091 · Cited by 32
de la Peña, A., Cui, X., Geiser, J., & Loghin, C. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0531-7 · Cited by 31
Bush, M., Scott, R., Watanalumlerd, P., Zhi, H., & Lewis, E. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.11.2613 · Cited by 30
Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
“Furthermore, the action of GLP-1 and GLP-1 RAs (especially short acting) on gastric and intestinal cells causes, respectively, the deceleration of gastric emptying [31] and the reduction in intestine motility [32], which both impact the absorption of nutrients.”
BackgroundEpprecht, L., Schreglmann, S. R., Goetze, O., Woitalla, D., Baumann, C. R., & Waldvogel, D. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7799-z · Cited by 12
Self-citationLupoli, R., Creanza, A., Griffo, E., Nardone, G., Rocco, A., Bozzetto, L., Annuzzi, G., Riccardi, G., & Capaldo, B. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02811 · Cited by 8
Metadata
- Authors
- Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A.
- Affiliations
- St. Josef-Hospital (DE)
- University of Copenhagen (DK)
- Diabeteszentrum Bad Lauterberg (DE)
- Corresponding author
- Meier, Juris J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-06
- Volume
- 88
- Issue
- 6
- Pages
- 2719-2725
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1987182389
- Cited by
- 369
- References
- 39
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 10 · 2023: 7 · 2022: 7 · 2021: 10 · 2020: 11 · 2019: 13 · 2018: 16 · 2017: 14 · 2016: 12 · 2015: 20 · 2014: 31 · 2013: 18 · 2012: 18
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, type 2 diabetes, glucose homeostasis, gastric emptying, insulin secretion, C-peptide, glucagon secretion, dose-response relationship, solid meal, breath test, intravenous infusion
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Fasting, Female, Gastric Emptying, Glucagon, Humans, Injections, Intravenous, Male, Middle Aged, Osmolar Concentration, Peptide Fragments, Protein Precursors, Time Factors, Postprandial Period, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.